Inhibition of Human Breast Cancer Cell Invasion by siRNA Against Urokinase-Type Plasminogen Activator

REFERENCES

• Guarneri, V.; Conte, P.F. The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging 2004, 31, S149–S161.
   PubMed Web of Science ®Google Scholar
• Vahdat, L.T. Clinical studies with epothilones for the treatment of metastatic breast cancer. Semin Oncol 2008, 35, 22–30.
   PubMed Web of Science ®Google Scholar
• Nozaki, S.; Endo, Y.; Nakahara, H.; Yoshizawa, K.; Ohara, T.; Yamamoto, E. Targeting urokinase-type plasminogen activator and its receptor for cancer therapy. Anticancer Drugs 2006, 17, 1109–1117.
   PubMed Web of Science ®Google Scholar
• Duffy, M.J. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004, 10, 39–49.
   PubMed Web of Science ®Google Scholar
• Dass, K.; Ahmad, A.; Azmi, A.S.; Sarkar, S.H.; Sarkar, F.H. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008, 34, 122–136.
   PubMed Web of Science ®Google Scholar
• Ploug, M. Structure–function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des 2003, 9, 1499–1528.
   PubMed Web of Science ®Google Scholar
• Castellino, F.J.; Ploplis, V.A. Structure and function of the plasminogen/plasmin system. Thromb Haemost 2005, 93, 647–654.
   PubMed Web of Science ®Google Scholar
• Lijnen, H.R. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001, 86, 324–333.
   PubMed Web of Science ®Google Scholar
• Pulukuri, S.M.; Gondi, C.S.; Lakka, S.S.; Jutla, A.; Estes, N.; Gujrati, M.; Rao, J.S. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 2005, 280, 36529–36540.
   PubMed Web of Science ®Google Scholar
• Subramanian, R.; Gondi, C.S.; Lakka, S.S.; Jutla, A.; Rao, J.S. siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells. Int J Oncol 2006, 28, 831–839.
   PubMed Web of Science ®Google Scholar
• Wang, Y. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med Res Rev 2001, 21, 146–170.
   PubMed Web of Science ®Google Scholar
• Gondi, C.S.; Lakka, S.S.; Yanamandra, N.; Siddique, K.; Dinh, D.H.; Olivero, W.C.; Gujrati, M.; Rao, J.S. Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene 2003, 22, 5967–5975.
   PubMed Web of Science ®Google Scholar
• Rao, J.S.; Gondi, C.; Chetty, C.; Chittivelu, S.; Joseph, P.A.; Lakka, S.S. Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol Cancer Ther 2005, 4, 1399–1408.
   PubMed Web of Science ®Google Scholar
• Duffy, M.J.; Maguire, T.M.; McDermott, E.W.; O’Higgins, N. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 1999, 71, 130–135.
   PubMed Web of Science ®Google Scholar
• Sidenius, N.; Blasi, F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003, 22, 205–222.
   PubMed Web of Science ®Google Scholar
• Sharp, P.A. RNAi and double-strand RNA. Genes Dev 1999, 13, 139–141.
   PubMed Web of Science ®Google Scholar
• Li, Q.X.; Zhao, J.; Liu, J.Y.; Jia, L.T.; Huang, H.Y.; Xu, Y.M.; Zhang, Y.; Zhang, R.; Wang, C.J.; Yao, L.B.; Chen, S.Y.; Yang, A.G. Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol Ther 2006, 5, 860–866.
   PubMed Web of Science ®Google Scholar
• Sumimoto, H.; Kawakami, Y. Lentiviral vector-mediated RNAi and its use for cancer research. Future Oncol 2007, 3, 655–664.
   PubMedGoogle Scholar
• Tan, F.L.; Yin, J.Q. Application of RNAi to cancer research and therapy. Front Biosci 2005, 10, 1946–1960.
   PubMed Web of Science ®Google Scholar
• Fu, H.J.; Jia, L.T.; Bao, W.; Zhao, J.; Meng, Y.L.; Wang, C.J.; Yao, L.B.; Chen, S.Y.; Yang, A.G. Stable knockdown of estrogen receptor alpha by vector-based RNA interference suppresses proliferation and enhances apoptosis in breast cancer cells. Cancer Biol Ther 2006, 5, 842–847.
   PubMed Web of Science ®Google Scholar
• Wen, W.H.; Liu, J.Y.; Qin, W.J.; Zhao, J.; Wang, T.; Jia, L.T.; Meng, Y.L.; Gao, H.; Xue, C.F.; Jin, B.Q.; Yao, L.B.; Chen, S.Y.; Yang, A.G. Targeted inhibition of HBV gene expression by single-chain antibody mediated small interfering RNA delivery. Hepatology 2007, 46, 84–94.
   PubMed Web of Science ®Google Scholar
• Choi, N.S.; Kim, S.H. Two fibrin zymography methods for analysis of plasminogen activators on gels. Anal Biochem 2000, 281, 236–238.
   PubMed Web of Science ®Google Scholar
• Kim, S.H.; Choi, N.S.; Lee, W.Y. Fibrin zymography: a direct analysis of fibrinolytic enzymes on gels. Anal Biochem 1998, 263, 115–116.
   PubMed Web of Science ®Google Scholar
• Ratnikov, B.I.; Deryugina, E.I.; Strongin, A.Y. Gelatin zymography and substrate cleavage assays of matrix metalloproteinase-2 in breast carcinoma cells overexpressing membrane type-1 matrix metalloproteinase. Lab Invest 2002, 82, 1583–1590.
   PubMed Web of Science ®Google Scholar
• Gupta, G.P.; Massague, J. Cancer metastasis: building a framework. Cell 2006, 127, 679–695.
   PubMed Web of Science ®Google Scholar
• Duffy, M.J.; McGowan, P.M.; Gallagher, W.M. Cancer invasion and metastasis: changing views. J Pathol 2008, 214, 283–293.
   PubMed Web of Science ®Google Scholar
• Van Der Burg, M.E.; Henzen-Logmans, S.C.; Berns, E.M.; van Putten, W.L.; Klijn, J.G.; Foekens, J.A. Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int J Cancer 1996, 69, 475–479.
   PubMed Web of Science ®Google Scholar
• Rosenberg, S. The urokinase-type plasminogen activator system in cancer and other pathological conditions: introduction and perspective. Curr Pharm Des 2003, 9: 4p following Table of Contents.
   PubMed Web of Science ®Google Scholar
• Schweinitz, A.; Steinmetzer, T.; Banke, I.J.; Arlt, M.J.; Sturzebecher, A.; Schuster, O.; Geissler, A.; Giersiefen, H.; Zeslawska, E.; Jacob, U.; Krüger, A.; Stürzebecher, J. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J Biol Chem 2004, 279, 33613–33622.
   PubMed Web of Science ®Google Scholar
• Arens, N.; Gandhari, M.; Bleyl, U.; Hildenbrand, R. In vitro suppression of urokinase plasminogen activator in breast cancer cells—a comparison of two antisense strategies. Int J Oncol 2005, 26, 113–119.
   PubMed Web of Science ®Google Scholar
• Sato, S.; Kopitz, C.; Schmalix, W.A.; Muehlenweg, B.; Kessler, H.; Schmitt, M.; Krüger, A.; Magdolen, V. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread. FEBS Lett 2002, 528, 212–216.
   PubMed Web of Science ®Google Scholar
• Miyagishi, M.; Hayashi, M.; Taira, K. Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev 2003, 13, 1–7.
   PubMedGoogle Scholar
• Zhang, Y.; Zhang, Y.F.; Bryant, J.; Charles, A.; Boado, R.J.; Pardridge, W.M. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 2004, 10, 3667–3677.
   PubMed Web of Science ®Google Scholar
• Ahmad, A.; Kong, D.; Wang, Z.; Sarkar, S.H.; Banerjee, S.; Sarkar, F.H. Down-regulation of uPA and uPAR by 3,3′-diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells. J Cell Biochem 2009, 108, 916–925.
   PubMed Web of Science ®Google Scholar
• Kunigal, S.; Lakka, S.S.; Gondi, C.S.; Estes, N.; Rao, J.S. RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer 2007, 121, 2307–2316.
   PubMed Web of Science ®Google Scholar
• Blasi, F.; Carmeliet, P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002, 3, 932–943.
   PubMed Web of Science ®Google Scholar